1208075-63-1

Basic information

• Product Name: Ethyl 2-Bromo-4-methoxybenzoate
• Synonyms: Ethyl 2-Bromo-4-methoxybenzoate
• CAS NO: 1208075-63-1
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259
• Mol File: 1208075-63-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 2-Bromo-4-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-Bromo-4-methoxybenzoate(1208075-63-1)
• EPA Substance Registry System: Ethyl 2-Bromo-4-methoxybenzoate(1208075-63-1)

Safety Data

• Hazardous Substances Data: 1208075-63-1(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 74317-85-4 2-bromo-4-methoxybenzoic acid 
• 89691-67-8 1-(2-bromo-4-methoxyphenyl)ethanone 
• 95-92-1 oxalic acid diethyl ester 
• 2398-37-0 3-methoxyphenyl bromide 

Downstream Products

• 74317-85-4 2-bromo-4-methoxybenzoic acid 
• 28547-28-6 2-bromo-4-hydroxybenzoic acid 
• 1446086-67-4 benzyl 2-bromo-4-hydroxybenzoate 
• 1446086-68-5 benzyl 2-(3-carbamoylphenyl)-4-hydroxybenzoate 
• 1446086-69-6 cyclohexylcarbamic acid 6-benzyloxycarbonyl-3′-carbamoylbiphenyl-3-yl ester 
• 1425459-40-0 cyclohexylcarbamic acid 3′-carbamoyl-6-carboxybiphenyl-3-yl ester 
• 1401160-81-3 4-methoxy-2-vinylbenzoic acid ethyl ester 

Relevant articles and documents

2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS

The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors

The peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor URB937 (3, cyclohexylcarbamic acid 3′-carbamoyl-6-hydroxybiphenyl-3-yl ester) is extruded from the brain and spinal cord by the Abcg2 efflux transporter. Despite its inability to enter the central nervous system (CNS), 3 exerts profound antinociceptive effects in mice and rats, which result from the inhibition of FAAH in peripheral tissues and the consequent enhancement of anandamide signaling at CB1 cannabinoid receptors localized on sensory nerve endings. In the present study, we examined the structure-activity relationships (SAR) for the biphenyl region of compound 3, focusing on the carbamoyl and hydroxyl groups in the distal and proximal phenyl rings. Our SAR studies generated a new series of peripherally restricted FAAH inhibitors and identified compound 35 (cyclohexylcarbamic acid 3′-carbamoyl-5- hydroxybiphenyl-3-yl ester) as the most potent brain-impermeant FAAH inhibitor disclosed to date.